Q1 2024 · 13F-HR
Frazier Life Sciences Management, L.P.holdings as filed
Filed 2024-05-15 · accession 0001892134-24-000003
$2.37B
Reported value
50
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $289.2M | 12.2% | 12,226,943 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $175.9M | 7.42% | 988,460 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $163.2M | 6.88% | 6,495,392 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $162.7M | 6.86% | 9,781,472 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $124.1M | 5.24% | 3,131,008 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $107.4M | 4.53% | 10,109,279 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $105.6M | 4.46% | 3,415,604 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $94.9M | 4.00% | 2,190,179 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $87.1M | 3.67% | 8,785,284 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $77.8M | 3.28% | 1,139,405 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $65.0M | 2.74% | 1,787,527 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $60.3M | 2.54% | 3,303,567 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $57.0M | 2.40% | 4,142,855 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $52.0M | 2.20% | 885,165 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $48.9M | 2.06% | 785,000 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $48.5M | 2.05% | 3,014,349 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $43.7M | 1.85% | 3,687,867 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $42.1M | 1.77% | 1,561,230 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $37.5M | 1.58% | 875,667 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $36.4M | 1.54% | 2,471,704 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $35.6M | 1.50% | 1,204,867 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $33.8M | 1.43% | 770,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $33.6M | 1.42% | 746,479 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $32.1M | 1.36% | 997,455 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $29.5M | 1.24% | 4,623,324 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $27.0M | 1.14% | 629,194 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $25.5M | 1.07% | 7,381,090 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $24.8M | 1.05% | 1,148,591 | Common | SOLE |
| 24344T101 | DCPHEUR | DECIPHERA PHARMACEUTICALS IN | $22.9M | 0.97% | 1,455,837 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $22.1M | 0.93% | 1,502,788 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $20.3M | 0.85% | 899,700 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $19.9M | 0.84% | 4,000,000 | Common | SOLE |
| 15678U128 | CERE1EUR | CEREVEL THERAPEUTICS HLDNG I | $16.6M | 0.70% | 393,000 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $15.3M | 0.65% | 523,166 | Common | SOLE |
| 00773U108 | ADVMCHF | ADVERUM BIOTECHNOLOGIES INC | $15.1M | 0.64% | 1,069,244 | Common | SOLE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $14.9M | 0.63% | 2,816,294 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $13.6M | 0.58% | 832,220 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $13.3M | 0.56% | 1,952,857 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS INC | $12.8M | 0.54% | 2,867,750 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $11.8M | 0.50% | 285,331 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $11.6M | 0.49% | 1,000,000 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $8.7M | 0.37% | 470,338 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $6.3M | 0.27% | 936,576 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $5.6M | 0.24% | 203,684 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $5.5M | 0.23% | 500,333 | Common | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $4.5M | 0.19% | 1,388,889 | Common | SOLE |
| 59102M104 | MGX | METAGENOMI INC | $2.9M | 0.12% | 279,025 | Common | SOLE |
| 39868T105 | 2JQ | GRITSTONE BIO INC | $2.6M | 0.11% | 1,030,878 | Common | SOLE |
| 09609G100 | — | BLUEBIRD BIO INC | $2.2M | 0.09% | 1,709,907 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $327,827 | 0.01% | 264,377 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.